At the Value Invest New York 2026 conference, Christina Malbon, CFA, Assistant Portfolio Manager at Patient Capital Management, presented three investment ideas that she believes the market has mispriced due to short-term concerns. Malbon, who has worked alongside Samantha McLemore since 2013, outlined how her team identifies opportunities where price deviates sharply from long-term fundamentals. “We buy stocks when they’re affordable, when there’s some sort of near-term question the market is hyper-focused on,” she explained. “It’s much easier to have confidence over three to five years than next quarter.”
Patient Capital Management’s philosophy centers on a simple but often uncomfortable premise: the best opportunities emerge precisely when the market is most anxious. Rather than chasing momentum, Malbon and her team look for companies where stock prices have detached from underlying business quality, situations where fear, uncertainty, or short-term headline risk have created a gap between what a business is worth and what investors are willing to pay for it.
Malbon looks for management teams willing to reinvest in the business, buy back shares below intrinsic value, and make capital allocation decisions that may look unconventional on a quarterly earnings call but compound shareholder value over years. “We’re looking for companies where we can make a case for what the business looks like over three to five years,” she said, “and where the current price doesn’t reflect that reality.”
Across all three of her picks, a common thread emerged: each company is a market leader in its respective industry, each is generating strong or improving cash flows, and each has been punished by the market for reasons Malbon believes are either temporary or fundamentally misunderstood. The result, she argued, is a rare window where investors can own high-quality businesses at valuations typically reserved for distressed or low-growth companies.

